NeoGenomics

NeoGenomics

NeoGenomics is a cancer diagnostics company headquartered in Fort Myers, Florida, originally founded in 2001 as a community hospital lab. The firm went public on the Nasdaq in 2012 under the ticker NEO, and has since grown through a combination of organic expansion and acquisitions, including the 2021 purchase of Inivata, a liquid biopsy firm, and the 2022 acquisition of OmniSeq, a immunogenomics company. The company's primary business lines include clinical oncology testing, pharma services for drug trials, and informatics solutions. As a publicly traded company, NeoGenomics reports revenue to the SEC—its fiscal year 2024 revenue was approximately $601 million, driven by roughly 535,000 test requisitions. The company's largest segments are clinical testing, which accounts for about 75% of revenue, and pharma services, which contributes the remainder. NeoGenomics operates labs in Fort Myers, Research Triangle Park, and Cambridge, UK, with a footprint extending across the United States and into Europe. The firm serves more than 3,500 hospital clients and over 300 pharmaceutical customers. NeoGenomics employs roughly 2,900 people and maintains a board of directors typical of a publicly traded corporation. The company does not operate as an investment vehicle; its capital structure relies on public equity markets and debt financing, not family-office allocations. In July 2024, the firm closed a $275 million convertible note offering to fund strategic initiatives (per SEC filing, July 2024). NeoGenomics differs from traditional family offices in that it is a revenue-generating operating business with a public market valuation. Its structural differentiation lies in its regulated healthcare business model—CLIA-certified and CAP-accredited laboratories—rather than in any asset management mandate.